KENALOG-10
Details
- Status
- Prescription
- First Approved
- 1960-01-04
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
KENALOG-10 Approval History
What KENALOG-10 Treats
14 indicationsKENALOG-10 is approved for 14 conditions since its original approval in 1960. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Gouty Arthritis
- Bursitis
- Tenosynovitis
- Epicondylitis
- Rheumatoid Arthritis
- Synovitis of Osteoarthritis
- Alopecia Areata
- Discoid Lupus Erythematosus
Drugs Similar to KENALOG-10
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KENALOG-10 FDA Label Details
ProIndications & Usage
FDA Label (PDF)The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Kenalog-10 Injection is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of gran...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.